Form Type:  SC 13G/A
Filing Date:  2/14/2020 
CIK:  0001080709 
Address:  6154 NANCY RIDGE DRIVE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-453-7200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.98 (1.62%)  
Trade Time: 
May 14  
Market Cap: 
Trade ARNA now with 

© 2021  
Description of Business
We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our internally developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Our most advanced investigational clinical programs include: etrasimod (APD334), being evaluated in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn's disease, or CD, and a Phase 2 program in alopecia areata, or AA. We also plan to evaluate etrasimod in a Phase 3 program in atopic dermatitis, or AD, and a Phase 2b program for eosinophilic esophagitis, or EoE. Olorinab (APD371) is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases and is currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome, or IBS.
Register and access this filing in: